

Topics today

- BioAdvance update
- Where is VC money going today?
- Regional landscape
- How to improve your odds of raising money

What is venture capital?

- Private money that takes greater risk in return for greater reward
 - Pension funds, endowments
 - Wealthy individuals & families
- Goal is to beat returns from public markets
- Organized into venture funds managed by investment professionals
- Model invest capital in 3 years; make money in 5 7 years

We're not a typical VC fund

- Evergreen / Not for profit
 - Started with \$20M
 - Goal was to help innovators, invest well and recycle returns
- Early-stage
- Human health focus
 - biopharm / therapeutics
 - medtech
 - digital health
- Mid-Atlantic focus

Where we are today

\$46M	invested in
92	companies, developing
95+	products, leveraging
\$2.8B	in additional dollars (a 1:61 leverage ratio) and
11	products approved by the FDA (plus 23 others marketed)

Examples of Recent Investments



New formulation of rapamycin for pachyonychia congenita - \$3M Series A-1; \$5M Series B



Anti-endothelin B to use with checkpoint inhibitors to activate T-cells - \$6.5M Series A



 $\times | \leftarrow | \leftarrow | \leftarrow | \rightarrow |$ Software to improve feeding management in the NICU - \$1.1M Seed; \$1.75M Series A

MNI


Medical food for cystic fibrosis - \$4.5M Series A

Renovaçor

Gene therapy for rare monogenic heart disease -\$11M Series A

Where is Venture Capital Going?

US venture capital at record levels







More money, more investors

- Increase in large mega-funds
- Increase in number of venture funds
- New kinds of investors
 - Disease foundations
 - Family offices
 - Angel groups
 - Accelerators
 - Health systems
 - Sovereign wealth funds
 - Out of left field: Ikea
 - Gov't translational funding (NIH, BARDA, etc)

But....


- Capital is concentrated geographically
 - 80% of companies who raised money in 2018 were in MA, CA or NY
- Capital is concentrated in fewer companies
 - More capital invested but # companies flat
 - Mega rounds (>\$100M) accounted for almost 50% of venture capital invested in 2018
 - Unicorns (over \$1B in valuation) took 35% of invested capital
- Venture funds creating their own companies

VC healthcare interest

- General rule: VC interest follows big pharma interest
- What's Hot
 - Immuno/oncology (\$4.4B)
 - Rare diseases (\$2B)
 - Gene and cell therapies
 - Platform companies
- What's Not
 - Infectious disease
 - Diagnostics
- Stage of Development
 - Half of VC funding for therapeutics went to pre-clinical companies



Greater Philadelphia VC Tracks US Growth



Source: Pitchbook






Greater Phila Healthcare Series A Deals: 2008 - 2018

Value 1 (bar graph): Total Capital Invested

Value 2 (line graph): Deal





Recent Greater Phila Series A deals













Investor base in PA/NJ/DE is small

Number of Active Investors by HQ State (All Sectors)

State	2017	2018
MA	183	137
NY	264	322
NJ	19	20
PA	44	34
DE	11	8
MD	19	29

Regional Investors in Healthcare

Angels (See www.angelcapitalassociation.org/)









Venture









Late Stage





Economic Development





Practical Tips

- Look outside the region for capital
- Raise enough money to get to a meaningful value creation / de-risking point
- Actively pursue non-traditional investors and sources of capital in parallel
- Network, research to find a fund that fits

Finding an investor that fits your opportunity

- Understand different types of investors
- The timing is right –a newly-closed fund is best
- The investor has capacity (5 deals/partner)
- You found an internal champion
- Your financing is the right size
- Your valuation is in the investor's comfort zone
- You are at the right stage of development and in a space that is in scope

Where to look for investors

Present at conferences

- JPMorgan (SFO)
- RESI (Boston and NYC)
- BIO
- Life Sciences Summit (NYC)
- HIMSS and SXSW (digital health)
- Read free newsletters to see who is active
 - Pitchbook News
 - Big4Bio
 - Fierce daily newsletters (Biotech; HealthIT, others)
 - Faster Cures
 - BIO Smart Brief

How to Improve the Odds of Raising Capital

The Basics

- 1. You solve an important problem no one else does
- 2. Investors can make money in a reasonable time frame
- 3. You have the right team/skillsets

1. You solve a problem

- What value do you bring--does your product solve a problem or create a benefit that someone will pay for?
 - Do you have evidence, such as data or customers?
- Is your product novel and differentiated?
- Is there a significant market opportunity?

2. Investors can make money

- Will you and investors be able to achieve a return through
 - Product sales
 - Acquisition by another company (exit)
 - Initial public offering
- In a reasonable time frame (4-6 years)
- At a valuation that is 3X-10X the amount of money you need to develop the product?
 - Rule of thumb--\$1 of investor money should create \$3-\$10 of value

3. You have the right team

The right kind of team has

- Skills that are relevant to the near-term plan
- A history of successful execution ("been there, done that")
- The ability to operate in a small company environment
- E.Q.

DON'T

- Hire your family
- Think that because you are a successful academic you can be a CEO
- Go it alone

We're Here to Help

We can give you input and feedback on multiple topics


- Where you fit in the capital landscape
- What kinds of technologies may be competitive
- What kind of investor might be appropriate
- At what stage BioAdvance would consider investing
- Suggestions for advisors (possibly team members) and other resources

How to Get Started

- Check BioAdvance website
 - FAQs
 - Team bios
 - Portfolio company list
- Send non-confidential information or ask for opportunity to get feedback/advice
 - Contact Marnie McCoy (<u>mmccoy@bioadvance.com</u>) or Barbara Schilberg (bschilberg@bioadvance.com)

www.bioadvance.com

Big4Bio Newsletter is Here!



Sign-up (it's free): Big4Bio.com